Lexaria Bioscience Corp, developers of the revolutionary DehydraTECH™ drug delivery technology, is in the news again this week. On October 13th, the British Columbia-based pharmaceutical company released study results on THC-A21-1, a THC oral format.The study revealed that Lexaria's DehydraTECH™ THC delivers THC levels to blood-plasma at a rate that is roughly three times faster than standard MCT-based THC. Oral ...

Lexaria Bioscience Corp, developers of the revolutionary DehydraTECH™ drug delivery technology, is in the news again this week. On October 13th, the British Columbia-based pharmaceutical company released study results on THC-A21-1, a THC oral format.

The study revealed that Lexaria's DehydraTECH™ THC delivers THC levels to blood-plasma at a rate that is roughly three times faster than standard MCT-based THC. Oral ingestion required just fifteen minutes to reach comparable levels that the "coconut-oil" formulations took forty-five minutes to achieve. By the six-hour mark, as THC was leaving the system, the levels were equal and demonstrated the fast-on, fast-off performance.

One of the key goals of this trial was to advance DehydraTECH™ THC as a medicinal solution, but CEO Chris Bunka is looking at a broader market. "THC consumers today include… medicinal and pharmaceutical users. Our objective is to provide them rapid onset and high bioavailability without harmful delivery mechanisms like smoking."

MORE Act Passes Another Congressional Hurdle

The DehydraTECH™ THC test results are timely because the House Judiciary Committee passed the MORE Act with a 26-15 majority vote just last week. There are still several hurdles to overcome, including final Senate approval, but the movement for federal legalization of cannabis in the United States appears to be gathering momentum again.

Canada (2018) and Mexico (2021) already have legalized cannabis on a national level. That includes medical marijuana. Eighteen US states, the District of Columbia, and Guam have also passed laws decriminalizing the use of cannabis and THC. The legal market for DehydraTECH™ THC in the US is estimated at 145 million Americans, based on US Census Bureau data.

With an increasing market size and a slim Senate majority in favor of national legalization, Lexaria's work in this area is critical. "The cannabis industry continues to use outdated formulations and processes," Chris Bunka said. "Our study demonstrated the rapid, safe THC delivery that is consistent with the wants and needs of today's THC consumers."

Medicinal Uses for THC Should Push Legislation Forward

The stigma of recreational THC use remains a stumbling block for Congressional action, but the documented benefits of using THC as a medical solution for pain relief should push legislation forward. According to the CDC, 93,331 people died from drug overdoses during the 2020 pandemic, many of them from pharmaceutical and synthetic opioids.

In recent years, the FDA has approved THC-based dronabinol (Marinol®) and nabilone (Cesamet®) as anti-nausea drugs for patients undergoing chemo treatments or suffering from AIDS-related wasting syndrome. The UK and Canada, along with several other European countries, are using THC/CBD formulations to treat neuropathic pain.

Lexaria is already well down the path to NDA filing for DehydraTECH™ CBD as an anti-hypertensive solution. That market is estimated at $30 billion. According to Grand View Research, the global legal cannabis market, which includes medicinal and recreational THC, was at $9.1 billion in 2020 and expected to grow at the rate of 26.7% from 2021 to 2028.

Disclaimer
This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its client's securities. See www.pcgadvisory.com/disclosures.

PCG Digital
info@pcgadvisory.com
646-863-6341

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100224

News Provided by Newsfile via QuoteMedia

Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Reports Third Quarter Results for 2021

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FSE:50N)(TSXV:NSP)(OTC PINK:NSPDF) announces its unaudited financial results for the nine months ended September 30, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid CEO Mr. Craig Goodwin reports, "The Company continues to execute on our strategic plan developing, manufacturing and distributing plant-based, meat alternative entrees. Having identified plant-based entrees as our priority, work has already begun retrofitting our existing food manufacturing facility located in British Columbia. This includes installation of a state-of-the-art packaging line which has already been initiated. This line is expected to be operational in the next 30 - 45 days. Once fully operational, this new packaging line creates significant opportunities in the retail market by providing a wide range of packaging formats that can then be placed in both chiller and freezer sections of grocery stores. The versatility of this packaging line creates opportunities for sales in multiple formats for different placement in stores across a wide range of potential clients, ultimately resulting in increased sales.

Keep reading... Show less

Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year

Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company's enduring commitment to environmental, social, and governance (ESG) issues. Amgen also was named to the DJSI North America Index for the ninth straight year.

The DJSI Indices are among the best indicators of a company's ESG performance due to the breadth of companies evaluated – nearly 11,000 this year – and the rigorous nature of the annual assessment process. The DJSI World Index recognizes the top 10% of companies in the S&P Global Broad Market Index for performance on ESG issues, which S&P Global considers critical to generating long-term stakeholder value.

Keep reading... Show less

Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS

ASCENT Subgroup Analysis Provides Insights on Treatment Outcomes for Black Patients with Metastatic TNBC –

Separate ASCENT Post Hoc Analysis Examines Outcomes in Patients Who Discontinue Treatment Due to Progressive Disease

Keep reading... Show less

Aptose to Hold Corporate Update Monday, December 13th

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting
Luxeptinib clinical update in AML and B-cell cancers

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Monday, December 13, 2021 at 5:30 PM ET, in conjunction with participation at the 2021 ASH Annual Meeting. The event will include a review of HM43239 data highlighted in an oral presentation at ASH, as well as the up-to-date clinical status of luxeptinib. HM43239 is an oral, myeloid kinome inhibitor in an international Phase 12 trial in patients with relapsed or refractory acute myeloid leukemia (AML). Luxeptinib is an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 ab trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 ab trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS)

Keep reading... Show less

Bristol Myers Squibb's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis

U.S. Food and Drug Administration assigned a target action date of September 10, 2022; European Medicines Agency validation confirms the submission is complete and begins the centralized review process

Keep reading... Show less

INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, CTXS, OWLT, PTON Investors, Lead Plaintiff Deadlines Set

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

Keep reading... Show less

Top News

Related News